Eugeen Vanmechelen

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6925112/publications.pdf

Version: 2024-02-01

119 papers	13,357 citations	20817 60 h-index	22166 113 g-index
126 all docs	126 docs citations	126 times ranked	9722 citing authors

#	Article	IF	Citations
1	Diagnostic and prognostic plasma biomarkers for preclinical Alzheimer's disease. Alzheimer's and Dementia, 2022, 18, 1141-1154.	0.8	89
2	Plasma pâ€tau231, pâ€tau181, <scp>PET</scp> Biomarkers, and Cognitive Change in Older Adults. Annals of Neurology, 2022, 91, 548-560.	5.3	42
3	Cerebrospinal fluid p-tau231 as an early indicator of emerging pathology in Alzheimer's disease. EBioMedicine, 2022, 76, 103836.	6.1	65
4	Comparing tau status determined via plasma pTau181, pTau231 and [18F]MK6240 tau-PET. EBioMedicine, 2022, 76, 103837.	6.1	34
5	Diagnostic value of serum versus plasma phospho-tau for Alzheimerâ€™s disease. Alzheimer's Research and Therapy, 2022, 14, 65.	6.2	25
6	Phosphoâ€specific plasma pâ€tau181 assay detects clinical as well as asymptomatic Alzheimer's disease. Annals of Clinical and Translational Neurology, 2022, 9, 734-746.	3.7	11
7	A Novel Neurofilament Light Chain ELISA Validated in Patients with Alzheimerâ€™s Disease, Frontotemporal Dementia, and Subjective Cognitive Decline, and the Evaluation of Candidate Proteins for Immunoassay Calibration. International Journal of Molecular Sciences, 2022, 23, 7221.	4.1	11
8	P-tau subgroups in AD relate to distinct amyloid production and synaptic integrity profiles. Alzheimer's Research and Therapy, 2022, 14, .	6.2	5
9	The Î²-Secretase BACE1 in Alzheimerâ€™s Disease. Biological Psychiatry, 2021, 89, 745-756.	1.3	336
10	Plasma Î²â€secretase1 concentrations correlate with basal forebrain atrophy and neurodegeneration in cognitively healthy individuals at risk for AD. Alzheimer's and Dementia, 2021, 17, 629-640.	0.8	10
11	Plasma p-tau231: a new biomarker for incipient Alzheimerâ€™s disease pathology. Acta Neuropathologica, 2021, 141, 709-724.	7.7	285
12	Comparing the Clinical Utility and Diagnostic Performance of CSF P-Tau181, P-Tau217, and P-Tau231 Assays. Neurology, 2021, 97, e1681-e1694.	1.1	60
13	Cerebrospinal fluid neurogranin in Alzheimerâ€™s disease studies: are immunoassay results interchangeable?. Clinical Chemistry and Laboratory Medicine, 2021, 60, e13-e17.	2.3	0
14	Clinical and analytical comparison of six Simoa assays for plasma P-tau isoforms P-tau181, P-tau217, and P-tau231. Alzheimer's Research and Therapy, 2021, 13, 198.	6.2	87
15	Association of brain network dynamics with plasma biomarkers in subjective memory complainers. Neurobiology of Aging, 2020, 88, 83-90.	3.1	4
16	Î²-Secretase1 biological markers for Alzheimerâ€™s disease: state-of-art of validation and qualification. Alzheimer's Research and Therapy, 2020, 12, 130.	6.2	16
17	CSF levels of the BACE1 substrate NRG1 correlate with cognition in Alzheimerâ€™s disease. Alzheimer's Research and Therapy, 2020, 12, 88.	6.2	20
18	BACE1 and Other Alzheimerâ€™s-Related Biomarkers in Cerebrospinal Fluid and Plasma Distinguish Alzheimerâ€™s Disease Patients from Cognitively-Impaired Neurosyphilis Patients. Journal of Alzheimer's Disease, 2020, 77, 313-322.	2.6	9

#	Article	IF	Citations
19	Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimerâ€™s continuum when only subtle changes in AÎ² pathology are detected. EMBO Molecular Medicine, 2020, 12, e12921.	6.9	202
20	Exploring molecular biomarkers with potential prognostic value in longitudinal observational studies on Alzheimerâ€™s disease. Alzheimer's and Dementia, 2020, 16, e047017.	0.8	0
21	A Novel Tau Antibody Detecting the First Amino-Terminal Insert Reveals Conformational Differences Among Tau Isoforms. Frontiers in Molecular Biosciences, 2020, 7, 48.	3.5	5
22	Pre-analytical stability of novel cerebrospinal fluid biomarkers. Clinica Chimica Acta, 2019, 497, 204-211.	1.1	9
23	Brain AÎ² load association and sexual dimorphism of plasma BACE1 concentrations in cognitively normal individuals at risk for AD. Alzheimer's and Dementia, 2019, 15, 1274-1285.	0.8	25
24	Plasma amyloid Î² 40/42 ratio predicts cerebral amyloidosis in cognitively normal individuals at risk for Alzheimer's disease. Alzheimer's and Dementia, 2019, 15, 764-775.	0.8	122
25	The elusive tau molecular structures: can we translate the recent breakthroughs into new targets for intervention?. Acta Neuropathologica Communications, 2019, 7, 31.	5.2	49
26	Synaptic biomarkers in CSF aid in diagnosis, correlate with cognition and predict progression in MCI and Alzheimer's disease. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2019, 5, 871-882.	3.7	79
27	Critical Steps to be Taken into Consideration Before Quantification of Î²-Amyloid and Tau Isoforms in Blood can be Implemented in a Clinical Environment. Neurology and Therapy, 2019, 8, 129-145.	3.2	8
28	Neurogranin as Cerebrospinal Fluid Biomarker for Alzheimer Disease: An Assay Comparison Study. Clinical Chemistry, 2018, 64, 927-937.	3.2	37
29	Digital ELISA for the quantification of attomolar concentrations of Alzheimer's disease biomarker protein Tau in biological samples. Analytica Chimica Acta, 2018, 1015, 74-81.	5.4	60
30	P1â€251: CSFâ€NEUROGRANIN, BUT NOT BACE1, IS AN ALZHEIMER'S DISEASE SPECIFIC BIOMARKER. Alzheimer's and Dementia, 2018, 14, P376.	0.8	0
31	Cerebrospinal fluid neurogranin/Î²â€site APPâ€cleaving enzyme 1 predicts cognitive decline in preclinical Alzheimer's disease. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2018, 4, 617-627.	3.7	24
32	Neurogranin and BACE1 in CSF as Potential Biomarkers Differentiating Depression with Cognitive Deficits from Early Alzheimerâ€™s Disease: A Pilot Study. Dementia and Geriatric Cognitive Disorders Extra, 2018, 8, 277-289.	1.3	20
33	Relevance of AÎ²42/40 Ratio for Detection of Alzheimer Disease Pathology in Clinical Routine: The PLMR Scale. Frontiers in Aging Neuroscience, 2018, 10, 138.	3.4	59
34	Neurogranin and tau in cerebrospinal fluid and plasma of patients with acute ischemic stroke. BMC Neurology, 2017, 17, 170.	1.8	70
35	The Cerebrospinal Fluid Neurogranin/BACE1 Ratio is a Potential Correlate of Cognitive Decline in Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2016, 53, 1523-1538.	2.6	46
36	Association of Plasma AÎ²40 Peptides, But Not AÎ²42, with Coronary Artery Disease and Diabetes Mellitus. Journal of Alzheimer's Disease, 2016, 52, 161-169.	2.6	18

#	Article	IF	Citations
37	Validation of soluble amyloidâ€Î² precursor protein assays as diagnostic <scp>CSF</scp> biomarkers for neurodegenerative diseases. Journal of Neurochemistry, 2016, 137, 112-121.	3.9	17
38	Assessing the commutability of reference material formats for the harmonization of amyloid-Î² measurements. Clinical Chemistry and Laboratory Medicine, 2016, 54, 1177-1191.	2.3	49
39	The utility of Î±-synuclein as biofluid marker in neurodegenerative diseases: a systematic review of the literature. Biomarkers in Medicine, 2016, 10, 19-34.	1.4	86
40	A First Tetraplex Assay for the Simultaneous Quantification of Total Î±-Synuclein, Tau, Î²-Amyloid42 and DJ-1 in Human Cerebrospinal Fluid. PLoS ONE, 2016, 11, e0153564.	2.5	6
41	P4-232: A monoclonal antibody-based elisa for neurogranin. , 2015, 11, P869-P869.		1
42	A Practical Guide to Immunoassay Method Validation. Frontiers in Neurology, 2015, 6, 179.	2.4	348
43	Tau Monoclonal Antibody Generation Based on Humanized Yeast Models. Journal of Biological Chemistry, 2015, 290, 4059-4074.	3.4	21
44	Validation of a quantitative cerebrospinal fluid alpha-synuclein assay in a European-wide interlaboratory study. Neurobiology of Aging, 2015, 36, 2587-2596.	3.1	30
45	TDP-43 as a possible biomarker for frontotemporal lobar degeneration: a systematic review of existing antibodies. Acta Neuropathologica Communications, 2015, 3, 15.	5.2	37
46	Câ€terminal neurogranin is increased in cerebrospinal fluid but unchanged in plasma in Alzheimer's disease. Alzheimer's and Dementia, 2015, 11, 1461-1469.	0.8	117
47	Monitoring of Î²-Amyloid Dynamics after Human Traumatic Brain Injury. Journal of Neurotrauma, 2014, 31, 42-55.	3.4	54
48	Tau as a molecular biomarker in cerebrospinal fluid and plasma. Neurobiology of Aging, 2014, 35, S23.	3.1	1
49	Increased CSF Î±â€synuclein levels in Alzheimer's disease: Correlation with tau levels. Alzheimer's and Dementia, 2014, 10, S290-8.	0.8	69
50	P2-127: TDP-43 AS A BIOMARKER FOR FRONTOTEMPORAL LOBE DEGENERATION: A SYSTEMATIC REVIEW OF EXISTING ANTIBODIES. , 2014, 10, P517-P518.		0
51	Functional Mannose-Binding Lectin Haplotype Variants are Associated with Alzheimer's Disease. Journal of Alzheimer's Disease, 2013, 35, 121-127.	2.6	12
52	Comparison of Two Analytical Platforms for the Clinical Qualification of Alzheimer's Disease Biomarkers in Pathologically-Confirmed Dementia. Journal of Alzheimer's Disease, 2012, 33, 117-131.	2.6	40
53	Evaluation of Plasma AÎ² as Predictor of Alzheimer's Disease in Older Individuals Without Dementia: A Population-Based Study. Journal of Alzheimer's Disease, 2012, 28, 231-238.	2.6	48
54	Potential sources of interference on Abeta immunoassays in biological samples. Alzheimer's Research and Therapy, 2012, 4, 39.	6.2	14

#	Article	IF	Citations
55	Recommendations to standardize preanalytical confounding factors in Alzheimerâ€™s and Parkinsonâ€™s disease cerebrospinal fluid biomarkers: an update. Biomarkers in Medicine, 2012, 6, 419-430.	1.4	280
56	Accuracy of a Panel of 5 Cerebrospinal Fluid Biomarkers in the Differential Diagnosis of Patients With Dementia and/or Parkinsonian Disorders. Archives of Neurology, 2012, 69, 1445.	4.5	407
57	Analytical aspects of molecular Alzheimerâ€™s disease biomarkers. Biomarkers in Medicine, 2012, 6, 377-389.	1.4	26
58	Identification of Novel Î±-Synuclein Isoforms in Human Brain Tissue by using an Online NanoLC-ESI-FTICR-MS Method. Neurochemical Research, 2011, 36, 2029-2042.	3.3	99
59	Evaluation of CSF Biomarkers as Predictors of Alzheimer's Disease: A Clinical Follow-Up Study of 4.7 Years. Journal of Alzheimer's Disease, 2010, 21, 1119-1128.	2.6	110
60	Neurogranin in cerebrospinal fluid as a marker of synaptic degeneration in Alzheimer's disease. Brain Research, 2010, 1362, 13-22.	2.2	180
61	Diagnosis-Independent Alzheimer Disease Biomarker Signature in Cognitively Normal Elderly People. Archives of Neurology, 2010, 67, 949.	4.5	407
62	Evaluation of plasma AÎ²40 and AÎ²42 as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment. Neurobiology of Aging, 2010, 31, 357-367.	3.1	242
63	Added diagnostic value of CSF biomarkers in differential dementia diagnosis. Neurobiology of Aging, 2010, 31, 1867-1876.	3.1	63
64	Evolution of AÎ²42 and AÎ²40 levels and AÎ²42/AÎ²40 ratio in plasma during progression of Alzheimer's disease: A multicenter assessment. Journal of Nutrition, Health and Aging, 2009, 13, 205-208.	3.3	52
65	Cerebrospinal fluid Î±-synuclein in neurodegenerative disordersâ€”A marker of synapse loss?. Neuroscience Letters, 2009, 450, 332-335.	2.1	194
66	Multiplexed quantification of dementia biomarkers in the CSF of patients with early dementias and MCI: A multicenter study. Neurobiology of Aging, 2008, 29, 812-818.	3.1	94
67	Diagnostic performance of a CSF-biomarker panel in autopsy-confirmed dementia. Neurobiology of Aging, 2008, 29, 1143-1159.	3.1	217
68	Biochemistry of Tau in Alzheimerâ€™s disease and related neurological disorders. Expert Review of Proteomics, 2008, 5, 207-224.	3.0	242
69	Characterization of Tau in Cerebrospinal Fluid Using Mass Spectrometry. Journal of Proteome Research, 2008, 7, 2114-2120.	3.7	74
70	Tau as a biomarker of neurodegenerative diseases. Biomarkers in Medicine, 2008, 2, 363-384.	1.4	83
71	No association of CSF biomarkers with APOEÂ4, plaque and tangle burden in definite Alzheimer's disease. Brain, 2007, 130, 2320-2326.	7.6	110
72	Intra-Individual Stability of CSF Biomarkers for Alzheimer's Disease over Two Years. Journal of Alzheimer's Disease, 2007, 12, 255-260.	2.6	117

#	Article	IF	Citations
73	Growth-associated protein 43 in lesions and cerebrospinal fluid in multiple sclerosis. Neuropathology and Applied Neurobiology, 2006, 32, 318-331.	3.2	22
74	Analytical performance and clinical utility of the INNOTESTÂ® PHOSPHO-TAU(181P) assay for discrimination between Alzheimer's disease and dementia with Lewy bodies. Clinical Chemistry and Laboratory Medicine, 2006, 44, 1472-80.	2.3	145
75	Subgroups of Alzheimer's disease based on cerebrospinal fluid molecular markers. Annals of Neurology, 2005, 58, 748-757.	5.3	144
76	Amino-Truncated Î²-Amyloid42 Peptides in Cerebrospinal Fluid and Prediction of Progression of Mild Cognitive Impairment. Clinical Chemistry, 2005, 51, 1650-1660.	3.2	82
77	The Effect of Simvastatin Treatment on the Amyloid Precursor Protein and Brain Cholesterol Metabolism in Patients with Alzheimerâ€™s Disease. Dementia and Geriatric Cognitive Disorders, 2005, 19, 256-265.	1.5	86
78	Simultaneous Measurement of Î²-Amyloid(1â€“42), Total Tau, and Phosphorylated Tau (Thr181) in Cerebrospinal Fluid by the xMAP Technology. Clinical Chemistry, 2005, 51, 336-345.	3.2	400
79	Phosphorylation of amyloid precursor carboxy-terminal fragments enhances their processing by a gamma-secretase-dependent mechanism. Neurobiology of Disease, 2005, 20, 625-637.	4.4	82
80	Measurement of Phosphorylated Tau Epitopes in the Differential Diagnosisof Alzheimer Disease. Archives of General Psychiatry, 2004, 61, 95.	12.3	390
81	Neurotoxicity Marker Profiles in the CSF are not Age-Dependent but Show Variation in Children Treated for Acute Lymphoblastic Leukemia. NeuroToxicology, 2004, 25, 471-480.	3.0	16
82	Plasma Levels of Î²-Amyloid(1-40), Î²-Amyloid(1-42), and Total Î²-Amyloid Remain Unaffected in Adult Patients With Hypercholesterolemia After Treatment With Statins. Archives of Neurology, 2004, 61, 333.	4.5	109
83	Glycosylation of acetylcholinesterase and butyrylcholinesterase changes as a function of the duration of Alzheimer's disease. Journal of Neuroscience Research, 2003, 72, 520-526.	2.9	55
84	Cerebrospinal fluid levels of total-tau, phospho-tau and AÎ²42 predicts development of Alzheimer's disease in patients with mild cognitive impairment. Acta Neurologica Scandinavica, 2003, 107, 47-51.	2.1	140
85	Truncated beta-amyloid peptide species in pre-clinical Alzheimer's disease as new targets for the vaccination approach. Journal of Neurochemistry, 2003, 85, 1581-1591.	3.9	196
86	Phospho-tau/total tau ratio in cerebrospinal fluid discriminates Creutzfeldtâ€“Jakob disease from other dementias. Molecular Psychiatry, 2003, 8, 343-347.	7.9	209
87	Unaltered Plasma Levels of Î²-Amyloid_(1â€“40) and Î²-Amyloid_(1â€“42) upon Stimulation of Human Platelets. Dementia and Geriatric Cognitive Disorders, 2003, 16, 93-97.	1.5	16
88	CSF markers for pathogenic processes in Alzheimerâ€™s disease: diagnostic implications and use in clinical neurochemistry. Brain Research Bulletin, 2003, 61, 235-242.	3.0	68
89	Cerebrospinal Fluid Beta-Amyloid 42 Is Reduced before the Onset of Sporadic Dementia: A Population-Based Study in 85-Year-Olds. Dementia and Geriatric Cognitive Disorders, 2003, 15, 169-176.	1.5	170
90	Decreased CSF-Î²-Amyloid 42 in Alzheimerâ€™s Disease and Amyotrophic Lateral Sclerosis May Reflect Mismetabolism of Î²-Amyloid Induced by Disparate Mechanisms. Dementia and Geriatric Cognitive Disorders, 2002, 13, 112-118.	1.5	125

#	Article	IF	Citations
91	Association of CSF apolipoprotein E, AÎ²42 and cognition in Alzheimerâ€™s disease. Neurobiology of Aging, 2002, 23, 205-211.	3.1	24
92	An in vitro model for the study of microglia-induced neurodegeneration: involvement of nitric oxide and tumor necrosis factor-Î±. Neurochemistry International, 2001, 38, 557-565.	3.8	68
93	Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke. Neuroscience Letters, 2001, 297, 187-190.	2.1	401
94	Low cerebrospinal fluid Î²-amyloid 42 in patients with acute bacterial meningitis and normalization after treatment. Neuroscience Letters, 2001, 314, 33-36.	2.1	71
95	Tau and AÎ²42 in Cerebrospinal Fluid from Healthy Adults 21â€“93 Years of Age: Establishment of Reference Values. Clinical Chemistry, 2001, 47, 1776-1781.	3.2	420
96	The Cerebrospinal Fluid Levels of Tau, Growth-Associated Protein-43 and Soluble Amyloid Precursor Protein Correlate in Alzheimerâ€™s Disease, Reflecting a Common Pathophysiological Process. Dementia and Geriatric Cognitive Disorders, 2001, 12, 257-264.	1.5	102
97	CSF Total tau, AÎ²42 and Phosphorylated tau Protein as Biomarkers for Alzheimer's Disease. Molecular Neurobiology, 2001, 24, 087-098.	4.0	232
98	Cerebrospinal fluid Ï„ and Î²-amyloid(1-42) in dementia disorders. Mechanisms of Ageing and Development, 2001, 122, 2005-2011.	4.6	50
99	Evaluation of CSF-tau and CSF-AÎ²42 as Diagnostic Markers for Alzheimer Disease in Clinical Practice. Archives of Neurology, 2001, 58, 373-9.	4.5	487
100	Identification of two-dimensionally separated human cerebrospinal fluid proteins byN-terminal sequencing, matrix-assisted laser desorption/ionization â€” mass spectrometry, nanoliquid chromatography-electrospray ionization-time of flight-mass spectrometry, and tandem mass spectrometry. Electrophoresis, 2000, 21, 2266-2283.	2.4	91
101	Disease- and treatment-related elevation of the neurodegenerative marker tau in children with hematological malignancies. Leukemia, 2000, 14, 2076-2084.	7.2	23
102	CSF levels of tau, Î²-amyloid 1-42 and GAP-43 in frontotemporal dementia, other types of dementia and normal aging. Journal of Neural Transmission, 2000, 107, 563-579.	2.8	227
103	Cerebrospinal Fluid Markers for Alzheimer's Disease Evaluated after Acute Ischemic Stroke. Journal of Alzheimer's Disease, 2000, 2, 199-206.	2.6	183
104	Cerebrospinal beta-amyloid (1â€“42) in early Alzheimer's disease: association with apolipoprotein E genotype and cognitive decline. Neuroscience Letters, 2000, 284, 85-88.	2.1	81
105	Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization. Neuroscience Letters, 2000, 285, 49-52.	2.1	452
106	Nonfibrillar diffuse amyloid deposition due to a gamma42-secretase site mutation points to an essential role for N-truncated Abeta42 in Alzheimer's disease. Human Molecular Genetics, 2000, 9, 2589-2598.	2.9	135
107	Standardization of measurement of Î²-amyloid‹sub›(1-42)‹/sub›in cerebrospinal fluid and plasma. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2000, 7, 245-258.	3.0	286
108	Cerebrospinal Fluid Î²-Amyloid(1-42) in Alzheimer Disease. Archives of Neurology, 1999, 56, 673.	4.5	594

#	Article	IF	Citations
109	Tau Immunoreactivity Detected in Human Plasma, But No Obvious Increase in Dementia. Dementia and Geriatric Cognitive Disorders, 1999, 10, 442-445.	1.5	31
110	Aberrant Splicing in the Presenilin-1 Intron 4 Mutation Causes Presenile Alzheimer's Disease by Increased ÂÂ42 Secretion. Human Molecular Genetics, 1999, 8, 1529-1540.	2.9	84
111	The Glu318Gly Substitution in Presenilin 1 Is Not Causally Related to Alzheimer Disease. American Journal of Human Genetics, 1999, 64, 290-292.	6.2	47
112	Evidence That AÎ²42 Plasma Levels in Presenilin-1 Mutation Carriers Do not Allow for Prediction of Their Clinical Phenotype. Neurobiology of Disease, 1999, 6, 280-287.	4.4	48
113	Cerebrospinal fluid tau and AÎ²42 as predictors of development of Alzheimer's disease in patients with mild cognitive impairment. Neuroscience Letters, 1999, 273, 5-8.	2.1	239
114	Postmortem changes in the phosphorylation state of tau-protein in the rat brain. Neurobiology of Aging, 1998, 19, 535-543.	3.1	57
115	Microtubule-associated protein tau in human fibroblasts with the Swedish Alzheimer mutation. Neuroscience Letters, 1996, 220, 9-12.	2.1	37
116	Developmental expression of tau proteins in the chicken and rat brain: Rapid downâ€regulation of a paired helical filament epitope in the rat cerebral cortex coincides with the transition from immature to adult tau isoforms. International Journal of Developmental Neuroscience, 1995, 13, 607-617.	1.6	29
117	Generation and characterization of mouse microglial cell lines. Journal of Neuroimmunology, 1994, 52, 153-164.	2.3	35
118	Detection of Proteins in Normal and Alzheimer's Disease Cerebrospinal Fluid with a Sensitive Sandwich Enzymeâ€Linked Immunosorbent Assay. Journal of Neurochemistry, 1993, 61, 1828-1834.	3.9	474
119	CSF Markers for Early Alzheimer's Disease. , 0, , 275-283.		0